2010-30201. Guidance on Institutional Review Board Approval of Research With Conditions  

  • Start Preamble Start Printed Page 74734

    AGENCY:

    Department of Health and Human Services, Office of the Secretary, Office of the Assistant Secretary for Health, Office for Human Research Protections.

    ACTION:

    Notice.

    SUMMARY:

    The Office for Human Research Protections (OHRP), Office of the Assistant Secretary for Health, is announcing the availability of a guidance document entitled “Guidance on IRB Approval of Research with Conditions.” The guidance document provides OHRP's first formal guidance on this topic. The document, which is available on OHRP's Web site at http://www.hhs.gov/​ohrp/​policy/​conditionalapproval2010.html or http://www.hhs.gov/​ohrp/​policy/​conditionalapproval2010.pdf,, is intended primarily for institutional review boards (IRB), investigators, Department of Health and Human Services (HHS) funding agencies, and others that may be responsible for the review, conduct, or oversight of human subject research conducted or supported by HHS. The guidance document announced in this notice finalizes the draft guidance that was made available for public comment through a notice in the Federal Register on November 6, 2009 (74 FR 57486). OHRP received comments on the draft guidance document from 12 individuals and organizations, and those comments were considered as the guidance was finalized.

    DATES:

    Comments on OHRP guidance documents are welcome at any time.

    ADDRESSES:

    Submit written requests for a single copy of the guidance document entitled, “Guidance on IRB Approval of Research with Conditions,” to the Division of Policy and Assurances, Office for Human Research Protections, 1101 Wootton Parkway, Suite 200, Rockville, MD 20852. Send one self-addressed adhesive label to assist that office in processing your request, or fax your request to 301-402-2071. See the SUPPLEMENTARY INFORMATION section for information on electronic access to the guidance document.

    Submit written comments to Comments on Conditional IRB Approval Guidance, Office for Human Research Protections, 1101 Wootton Parkway, Suite 200, Rockville, MD 20852. Comments also may be sent via e-mail to ohrp@hhs.gov or via facsimile at 240-402-2071.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Irene Stith-Coleman, PhD, Office for Human Research Protections, 1101 Wootton Parkway, Suite 200, Rockville, MD 20852, 240-453-6900; e-mail Irene.Stith-Coleman@hhs.gov.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    I. Background

    OHRP is announcing the availability of a guidance document entitled “Guidance on IRB Approval of Research with Conditions.” The guidance document provides OHRP's first formal guidance on this topic. The document is intended primarily for IRBs, investigators, HHS funding agencies, and others that may be responsible for the review, conduct, or oversight of human subject research conducted or supported by HHS.

    The guidance document applies to non-exempt human subjects research conducted or supported by HHS. It provides guidance on the authority of IRBs to approve research with conditions. In particular, the guidance addresses the following nine topics:

    (1) What actions can an IRB take when reviewing research?

    (2) What does IRB approval with conditions mean?

    (3) What circumstances preclude the IRB from approving research?

    (4) What circumstances permit the IRB to approve research with conditions?

    (5) How should the IRB handle changes to research that are proposed after the IRB has approved the research with conditions?

    (6) How do conditions on IRB approval at the time of initial review affect the initiation of research?

    (7) May an IRB approve some components of a proposed research study and defer taking action on other components at the time of initial review?

    (8) How do conditions on IRB approval at the time of continuing review, or at the time of review of proposed changes in previously approved research, affect ongoing research?

    (9) What must the IRB records include regarding the documentation of conditions of IRB approval of research?

    The guidance document announced in this notice finalizes the draft guidance that was made available for public comment through a notice in the Federal Register on November 6, 2009 (74 FR 57486). OHRP received comments on the draft guidance document from 12 individuals and organizations, and those comments were considered as the guidance was finalized. The majority of commenters expressed general support for the draft guidance document. The final guidance document is largely unchanged from what was proposed in the draft guidance, with only minor clarifying edits made in response to many of the comments.

    II. Electronic Access

    The guidance document is available on OHRP's Web site at http://www.hhs.gov/​ohrp/​policy/​conditionalapproval2010.html or http://www.hhs.gov/​ohrp/​policy/​conditionalapproval2010.pdf.

    III. Comments

    Interested persons may submit comments regarding this guidance document to OHRP at any time. Please see the ADDRESSES section for information on where to submit written comments.

    Start Signature

    Dated: November 24, 2010.

    Jerry Menikoff,

    Director, Office for Human Research Protections.

    End Signature End Supplemental Information

    [FR Doc. 2010-30201 Filed 11-30-10; 8:45 am]

    BILLING CODE 4150-36-P

Document Information

Comments Received:
0 Comments
Published:
12/01/2010
Department:
Health and Human Services Department
Entry Type:
Notice
Action:
Notice.
Document Number:
2010-30201
Dates:
Comments on OHRP guidance documents are welcome at any time.
Pages:
74734-74734 (1 pages)
PDF File:
2010-30201.pdf
Supporting Documents:
» Patient Protection and Affordable Care Act: Benefit and Payment Parameters for 2022; Updates to State Innovation Waiver Implementing Regulations
» Guidance: Good Guidance Practices; Correction
» National Vaccine Injury Compensation Program: Revisions to the Vaccine Injury Table
» Amendments to the HHS-Operated Risk Adjustment Data Validation Under the Patient Protection and Affordable Care Act's HHS-Operated Risk Adjustment Program
» Transparency in Coverage
» UA: Reg Flex Agenda
» Medicare and Medicaid Programs: CY 2020 Hospital Outpatient PPS Policy Changes and Payment Rates and Ambulatory Surgical Center Payment System Policy Changes and Payment Rates; Price Transparency Requirements for Hospitals to Make Standard Charges Public
» Administrative Simplification: Rescinding the Adoption of the Standard Unique Health Plan Identifier and Other Entity Identifier
» Protecting Statutory Conscience Rights in Health Care; Delegations of Authority
» Patient Protection and Affordable Care Act: Increasing Consumer Choice through the Sale of Individual Health Insurance Coverage Across State Lines Through Health Care Choice Compacts